On Friday, QEP Resources Inc (NYSE:QEP)’s shares inclined 0.53% to $13.24.
QEP Resources, Inc. (QEP) declared that members of the Company’s senior administration will take part in the forthcoming Barclays CEO Energy/Power Conference on Thursday, September 10, 2015 at 9:05 a.m. EDT (7:05 a.m. MDT). A link to the webcast and a copy of the presentation will be accessible at www.qepres.com. Attendees should log in to the webcast about 15 minutes proceeding to the presentation’s start time. A replay of the webcast will be accessible for about 30 days through a link on the Company’s website at www.qepres.com.
QEP Resources, Inc., through its auxiliaries, operates as an exploration and production company. The company acquires, explores, develops, and produces natural gas, oil, and natural gas liquids (NGLs) primarily in the Pinedale Anticline in western Wyoming; the Williston Basin in North Dakota; the Uinta Basin in eastern Utah; the Permian Basin in western Texas; the Haynesville/Cotton Valley in northwestern Louisiana; and other proven properties in Wyoming, Utah, and Colorado.
Prospect Capital Corporation (NASDAQ:PSEC)’s shares gained 1.95% to $7.84.
Prospect Capital Corporation (NASDAQ: PSEC) declared financial results for our fourth fiscal quarter ended June 30, 2015.
For the June 2015 quarter, our enhance in net assets resulting from operations (“net income” or “NI”) was $94.8 million or $0.26 per weighted average share. For the June 2014 quarter, our NI was $71.7 million or $0.21 per weighted average share. NI raised 32% year-over-year on a dollars basis and raised by $0.05, or 24%, on a per share basis due to net realized and unrealized gains in 2015 as compared to net realized and unrealized losses in 2014.
For the June 2015 quarter, our net investment income (“NII”) was $89.5 million or $0.25 per weighted average share. For the June 2014 quarter, our NII was $84.1 million or $0.25 per weighted average share. NII raised by $5.4 million year-over-year on a dollars basis and remained comprising on a per share basis, driven primarily by an enhance in interest income. Comprised Of within NII was an enhance in recurring interest income year-over-year by $19.2 million, or $0.03 on a per share basis. Our recurring income as measured by the percentage of total investment income from interest income was 96.1% in the June 2015 quarter.
At the end of Friday’s trade, Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)‘s shares dipped -1.88% to $171.98.
Alexion Pharmaceuticals, Inc. (ALXN) declared recently that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for its Precedingity Review of the Company’s Biologics License Application (BLA) for Kanuma™ (sebelipase alfa), an investigational enzyme replacement therapy for the treatment of lysosomal acid lipase deficiency (LAL-D). The formerly revealed September 8, 2015 PDUFA date has been extended by the standard extension period of three months.
In response to a recent request from the FDA, Alexion presented additional Chemistry, Manufacturing and Controls (CMC) information. Due to the timing of this submission, the FDA extended the PDUFA date to allow additional time for review of the new information. The FDA has not asked for additional clinical data.
On September 1, 2015, Alexion declared that the European Commission approved Kanuma for the treatment of patients of all ages with LAL-D. The FDA granted Breakthrough Therapy designation for Kanuma for LAL Deficiency presenting in infants and accepted the Kanuma BLA for Preceding Review. In addition, a New Drug Application for Kanuma has been presented to Japan’s Ministry of Health, Labour and Welfare.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH and aHUS registry; Phase III clinical trials for the treatment of delayed kidney transplant graft function and myasthenia gravis; and Phase II clinical trials for the treatment of antibody mediated rejection in presensitized kidney transplant patients and neuromyelitis optica.
Callon Petroleum Company (NYSE:CPE), ended its Friday’s trading session with -0.77% loss, and closed at $9.05.
Callon Petroleum Company (CPE) declared that it has declared a cash dividend of $1.25 per share on its 10.0% Series A Cumulative Preferred Stock (“Series A Preferred Stock”). The dividend will be paid on September 30, 2015 to stockholders of record as of September 14, 2015. The Series A Preferred Stock is presently listed on the New York Stock Exchange under the symbol “CPE.A.”
Callon Petroleum Company engages in the exploration, development, acquisition, and production of oil and natural gas properties in the Permian Basin in West Texas. As of December 31, 2014, its estimated net proved reserves totaled 32.8 million barrel of oil equivalent, counting 25.7 million barrels of oil and 42.5 billion cubic feet of natural gas. The company was founded in 1950 and is headquartered in Natchez, Mississippi.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
